Interim Report 1 January – 30 September 2023
· US: Commercial business started promising with the first surgeries performed. 510(k) application for Episealer® MTP-system submitted · OUS: Continued steady growth driven by continued strong growth in customer base · Execution of re-structuring program ongoing”In connection with the report for the third quarter of 2023, we clearly show we are on the right track. The expansion of the business model, both in terms of the product portfolio and geographies, is now showing clear progress, and we expect this development to continue at an increasingly rapid pace. While posting 86% revenue